Immuneering Corporation reports clinical oncology developments centered on Deep Cyclic Inhibitors, a category of cancer medicines the company is developing for durability, tolerability and combinability. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK being studied across MAPK pathway-driven tumors, including pancreatic cancer.
Recurring updates include survival and safety data from atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, molecular and circulating tumor DNA analyses tied to MAPK resistance mechanisms, and presentations at oncology meetings such as ASCO and AACR. Company news also covers financial results, R&D spending, pipeline strategy, regulatory-readiness activities and healthcare-conference presentations.
Immuneering (IMRX) will present an atebimetinib research poster at the Society for Immunotherapy of Cancer meeting on November 6, 2026.
The company reports that atebimetinib enhances PD-1 checkpoint blockade, an immune-based cancer treatment, in preclinical RAS mutant tumor models. The findings support its planned Phase 2 lung cancer study combining the treatments. The meeting runs November 4–8 in Phoenix, Arizona.
Immuneering (IMRX) presented exploratory Phase 2a pancreatic cancer data examining weight preservation, tumor shrinkage and survival during atebimetinib combination treatment.
Among evaluable patients receiving atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP), 84% had stable or increased weight at three months. In a new analysis of 23 evaluable patients, that outcome was approximately twice as common as in a published benchmark study. Patients with stable or increased weight at three months lived longer than those who lost weight (p=0.049). Survival was comparable between patients with moderate and deeper tumor reductions. The analyses were post-hoc and came from a single-arm study; a Phase 3 trial is enrolling first-line patients.
Immuneering (IMRX) will present a poster on its ongoing Phase 3 MAPKeeper 301 pancreatic cancer trial at ESMO on October 25, 2026.
The randomized, open-label study compares atebimetinib plus modified gemcitabine/nab-paclitaxel with standard gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The ESMO Congress runs October 23–27 in Madrid. Full abstracts are scheduled for publication on October 19.
Immuneering (IMRX) will present a poster on atebimetinib’s effects in pancreatic ductal adenocarcinoma (PDAC) at the AACR Conference on Pancreatic Cancer, held September 25-28, 2026, in San Diego.
The work expands on earlier findings that 84% of evaluable first-line PDAC patients treated with atebimetinib plus mGnP maintained or gained weight at three months and includes new analyses of the overall survival implications of preserving body mass and reducing tumor volume. The poster, titled “Atebimetinib Reduces Tumor Volume and Preserves Body Mass: A Dual Mechanism for Extended Survival in Pancreatic Cancer,” will be presented by Peter Vu, M.D., MHA, on September 26, 2026, from 6:00–8:00 pm PT (Poster A134) in room Indigo CDCH.
Immuneering (IMRX) will participate in two New York investor conferences in September 2026, featuring fireside chats and 1x1 investor meetings.
Management will appear at the Cantor Global Healthcare Conference on Thursday, September 10, 2026, from 2:45–3:15 pm ET, and at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, from 5:00–5:30 pm ET. Both fireside chats will be webcast live and later archived in the Investor Relations section of Immuneering’s website.
Immuneering (Nasdaq: IMRX) commented on the FDA’s newly approved second-line metastatic pancreatic cancer treatment and reiterated its focus on first-line patients. The company emphasized that its MEK inhibitor atebimetinib is being evaluated in the global, randomized, pivotal Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer, which is now enrolling and lists more than 35 sites on ClinicalTrials.gov.
Immuneering highlighted previously reported Phase 2a data in 55 first-line metastatic pancreatic cancer patients treated with atebimetinib 320 mg once daily plus modified gemcitabine/nab-paclitaxel. As of the April 24, 2026 cutoff, median overall survival was 17.3 months with median follow-up of 11.6 months; 84% of evaluable patients maintained or gained weight at three months. The only Grade 3 or higher treatment-related adverse events occurring in ≥10% of patients were anemia (16%) and neutropenia (18%), both described as chemotherapy-related.
Immuneering (Nasdaq: IMRX) reported second quarter 2026 results and business updates, highlighting its lead Deep Cyclic Inhibitor, atebimetinib. In a single-arm Phase 2a trial in first-line metastatic pancreatic cancer, atebimetinib plus modified gemcitabine/nab-paclitaxel showed a 17.3 month median overall survival in 55 patients, with 84% of evaluable patients weight stable or gaining weight at three months and limited high-grade treatment-related adverse event categories. A pivotal global Phase 3 trial, MAPKeeper 301, is underway with patients dosed and over 30 sites posted.
Immuneering ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities and expects its cash runway to extend into 2029. Q2 R&D expenses were $14.0 million and G&A expenses $5.0 million, leading to a net loss of $17.3 million, or $0.27 per share.
Immuneering (Nasdaq: IMRX) reported that peer‑reviewed data in Cancer Research describe atebimetinib’s differentiated mechanism and broad preclinical activity in RAS‑ and RAF‑mutant tumor models, including colorectal, lung, and melanoma. Atebimetinib simultaneously inhibited pERK and pMEK and resisted RAF‑mediated bypass signaling seen with other MEK inhibitors.
In head‑to‑head in vivo studies, atebimetinib achieved deeper, more durable tumor growth inhibition than FDA‑approved MEK inhibitor binimetinib while remaining well tolerated, with mice generally maintaining body weight within a 3–5% range. According to Immuneering, atebimetinib is being evaluated in the Phase 3 MAPKeeper 301 trial in metastatic pancreatic cancer, with a Phase 2 trial in RAS‑mutant NSCLC expected to start dosing in the second half of the year.
Immuneering (Nasdaq: IMRX) granted stock options as inducement awards tied to new hires effective July 16, 2026. New Chief Financial Officer Andrew Gengos received an option to purchase 650,000 Class A common shares at an exercise price of $4.78, equal to the July 16, 2026 Nasdaq closing price. The ten-year option, issued under the 2025 Employment Inducement Award Plan and approved by the Board, vests monthly over four years, becoming fully vested on the fourth anniversary of his start date.
On the same date, a non-executive employee received an option for 32,400 shares at the same exercise price, vesting 25% on July 16, 2027 and the remaining 75% in substantially equal monthly installments through July 16, 2030. Both grants were made under Nasdaq Rule 5635(c)(4) as material inducements to employment.
Immuneering (Nasdaq: IMRX) appointed Andrew Gengos as Chief Financial Officer, effective July 16, 2026. He previously served as CFO and Head of Corporate Development at Terns Pharmaceuticals, which Merck acquired for $6.7 billion.
Gengos will oversee financial strategy as Immuneering advances Phase 3 oncology candidate atebimetinib and its deep cyclic inhibitor pipeline.